SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
CAR-T, CD19

Yescarta More Cost-Effective Compared to Kymriah but With Higher CRS and NT Rates; Updated Results From Kymriah’s Ph1b PORTIA Trial; POC CD19 CAR-Ts Outperform OOS Kymriah; EHA 2021 Day 1

Here is a brief preview of this blast: On the first day of EHA 2021, seven key clinical updates were presented from Novartis, Gilead, the Sheba Medical Center, and the Fred Hutchinson Cancer Center. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.